Ventures

The challenge with lung cancer lies in its late detection, often leading to unfortunate outcomes. Current screening methods like low-dose CT scans are costly and have radiation risks, while blood tests lack accuracy or are too expensive. Our solution offers a non-invasive blood test that detects lung cancer early with high sensitivity and specificity. This test, with its multi-protein panel, can identify even stage I cancer, improving survival rates and reducing unnecessary procedures.

The traditional practice of immediately cutting the umbilical cord after birth can pose risks to newborns, causing a dangerous drop in blood flow and oxygen levels. Concord Neonatal offers a solution by allowing babies to receive lifesaving care with the umbilical cord intact until they start breathing on their own. This innovation, aims to prevent birth complications and long-term disabilities, while keeping the baby close to the mother and maximizing the benefits of placental blood until the baby can breathe independently.

HapticHeart Solutions is revolutionizing cardiac procedures by giving cardiologists a "sense of touch" during catheter-based surgeries. These surgeries, which are becoming more complex, often require delicate maneuvers inside the heart. Their wearable device translates signals from the cath lab into tactile feedback, allowing cardiologists to feel what's happening inside the patient's heart. This helps them navigate catheters more effectively and focus on critical aspects of the procedure, leading to safer and more efficient surgeries with better outcomes for patients.

With over 50 million people living with Alzheimer's and numbers expected to triple by 2050, there's an urgent need for effective treatments. Alzheimer's is a leading cause of death and imposes a global economic burden of $1 trillion annually. Our novel DYRK1A inhibitor aims to slow or even reverse Alzheimer's progression by targeting key pathways with high specificity and effective blood-brain barrier penetration. This innovative small molecule offers superior disease-modifying potential, addressing current treatment limitations and providing new hope for patients and healthcare systems worldwide.

Sansepsis is a new treatment for sepsis, a serious condition causing many hospital deaths. Developed by Sanquin, a top blood bank in Europe, it uses a special filtering technology called apheresis to remove harmful pathogens from the blood. This innovative approach aims to improve patient outcomes and reduce the high costs associated with treating sepsis, offering hope for better management of this deadly condition.

PCaVision, offers an ultrasound-based solution for detecting, localizing, and characterizing prostate cancer. Each year, over 1.5 million men undergo invasive biopsies with risks of infection, false negatives, and overtreatment. PCaVision eliminates these issues by providing a non-invasive, accurate, and cost-effective alternative, improving patient comfort and outcomes. With an estimated market value of USD 450 million annually, PCaVision addresses a significant global need for better prostate cancer diagnostics.

Rare diseases often lead to years of diagnostic odyssey and immense patient suffering. Therefore Genorare is set to dramatically shorten this diagnostic journey for individuals with rare diseases. Genorare's platform enables real-time, secure analysis of genomic, clinical, and phenotypic data using Large Language Models, predictive analytics, and Fully Homomorphic Encryption. A key innovation is the use of Fully Homomorphic Encryption, a next-generation privacy technology that allows for advanced analysis while ensuring patient data remains completely secure, promising a new standard of care for the rare disease community.

Kaminari Medical is innovating coronary artery disease treatment with a catheter, combining intravascular ultrasound (IVUS) and photoacoustic imaging (PA). This IVPA technology provides precise information on plaque location and structure, enabling doctors to identify and treat dangerous plaques preemptively. By enhancing the accuracy of stent placements and guiding medication therapy, IVPA is expected to prevent 50% of re-catheterizations, reducing repeated procedures and saving over €1 billion annually.